AR056194A1 - Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular - Google Patents
Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascularInfo
- Publication number
- AR056194A1 AR056194A1 ARP060103941A ARP060103941A AR056194A1 AR 056194 A1 AR056194 A1 AR 056194A1 AR P060103941 A ARP060103941 A AR P060103941A AR P060103941 A ARP060103941 A AR P060103941A AR 056194 A1 AR056194 A1 AR 056194A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- unsubstituted
- alkylene
- alkyl
- independently selected
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 239000003102 growth factor Substances 0.000 title 1
- 230000002792 vascular Effects 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 108091008605 VEGF receptors Proteins 0.000 abstract 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 3
- 125000004450 alkenylene group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- -1 di-substituted amino Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 1
- WHOWNXIYXLWMGJ-UHFFFAOYSA-N 1-(pyridin-4-ylmethyl)phthalazine Chemical class N=1N=CC2=CC=CC=C2C=1CC1=CC=NC=C1 WHOWNXIYXLWMGJ-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000001841 imino group Chemical group [H]N=* 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 239000003961 penetration enhancing agent Substances 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Una composicion que comprende un inhibidor del receptor del factor de crecimiento endotelial vascular y un potenciador de la penetracion, y usos de la misma. Reivindicacion 2: Una composicion de la reivindicacion 1, en donde el inhibidor del receptor del factor de crecimiento endotelial vascular es un compuesto de formula(1), en donde R1 es H; halogeno; -(C0-7)-R3; -(C0-7)-NR4R5; o -C(=O)-R6; R2 cicloalquilo C3-8 substituido; arilo substituido; o heterociclilo substituido; R3 es H o alquilo C1-4 insubstituido o substituido; R4 y R5 se seleccionan independientemente a partir del grupo que consiste en H; alquilo C1-4 insubstituido o substituido; alquil C1-4-carbonilo, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; y alcoxi C1-4-carbonilo, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; R6 es H; alquilo C1-4 insubstituido o substituido; aIcoxilo C1-4, en donde la fraccion de alquilo C1-4 está opcionalmente substituida; o amino insubstituido, mono- o di-substituido; A, B y X se seleccionan independientemente a partir de =C(R7)- o N; E, G y T se seleccionan independientemente a partir de =C(R8)- o N; R7 y R8 se seleccionan independientemente a partir del grupo que consiste en H, halogeno y alquilo C1-4 insubstituido o substituido; Y es -O-, -S-, -S(O)-, -S(O)2-, -CH2- o -CH2-CH2-; Z es CH o N y Q es alquileno C1-4 o alquenileno C2-4 en donde alquileno C1-4 o alquenileno C2-4 pueden estar opcionalmente substituidos y en donde uno o más de los átomos de carbono de esta cadena de alquileno C1-4 o alquenileno C2-4 pueden ser opcionalmente reemplazados por un heteroátomo independientemente seleccionado a partir de nitrogeno, oxígeno y azufre; y el enlace entre Q y Z caracterizado por una línea punteada es un enlace individual; con la condicion de que si Z es N, Q no es alquileno insubstituido no ramificado; o Z es C y Q es como se define anteriormente, en donde el enlace entre Q y Z caracterizado por una línea punteada es un doble enlace; y W no está presente o es alquileno C1-3; o un compuesto de formula (2), en donde R9 y R10 son cada uno independientemente uno del otro, hidrogeno, alquilo C1-7 insubstituido o substituido o cicloalquilo C3-8, un radical heterocíclico enlazado por medio de un átomo de carbono del anillo, o un radical de la formula R12-Y-(C=Z)-, en donde R12 es amino insubstituido, mono-, o di-substituido o un radical heterocíclico, Y no está presente o es alquilo C1-8 y Z es O, S o imino, con la condicion de que R9 y R10 no sean ambos hidrogeno; o R9 y R10 junto con el átomo de nitrogeno con el que están unidos forman un radical heterocíclico; R11 es un radical heterocíclico o un radical aromático insubstituido o substituido; K es alquileno C1-7, -C(=O)-, o alquileno C1-6-C(=O)-, en donde el grupo carbonilo está unido a la fraccion NR9R10; M es -NH- u -O-, con la condicion de que M es -O- si K es -C(=O)- o alquileno C1-6-C(=O)-; y V no está presente o es alquileno C1-7, con la condicion de que un radical heterocíclico R11 está enlazado por medio de un átomo de carbono del anillo si V no está presente, o un tautomero del mismo; o un derivado de 4-piridilmetil-ftalazina; o un tautomero del mismo, o en la forma de una sal, un solvente, o en la forma de una sal y un solvente. Reivindicacion 6: Una composicion de cualquiera de las reivindicaciones 1 a 5, en donde el inhibidor del receptor del factor de crecimiento endotelial vascular es un compuesto de la formula (3) o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0518672A GB0518672D0 (en) | 2005-09-13 | 2005-09-13 | Organic compounds |
| GB0518671A GB0518671D0 (en) | 2005-09-13 | 2005-09-13 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056194A1 true AR056194A1 (es) | 2007-09-26 |
Family
ID=37663150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060103941A AR056194A1 (es) | 2005-09-13 | 2006-09-11 | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20080306058A1 (es) |
| EP (1) | EP1945217B1 (es) |
| JP (1) | JP2009507871A (es) |
| KR (1) | KR20080058376A (es) |
| AR (1) | AR056194A1 (es) |
| AT (1) | ATE555790T1 (es) |
| AU (1) | AU2006291526B2 (es) |
| BR (1) | BRPI0615881A2 (es) |
| CA (1) | CA2621399A1 (es) |
| EC (1) | ECSP088259A (es) |
| GT (1) | GT200600411A (es) |
| IL (1) | IL189984A0 (es) |
| MA (1) | MA29788B1 (es) |
| MY (1) | MY145751A (es) |
| NO (1) | NO20081807L (es) |
| NZ (1) | NZ566474A (es) |
| PE (1) | PE20070457A1 (es) |
| RU (1) | RU2424804C2 (es) |
| SA (1) | SA06270315B1 (es) |
| SG (1) | SG165371A1 (es) |
| TN (1) | TNSN08112A1 (es) |
| TW (1) | TWI325321B (es) |
| WO (1) | WO2007031265A2 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0605120D0 (en) | 2006-03-14 | 2006-04-26 | Novartis Ag | Organic Compounds |
| WO2008125691A2 (en) | 2007-04-17 | 2008-10-23 | Novartis Ag | Ethers of naphtalene carboxylic acid amides as cancer cure |
| EP2559686A1 (en) * | 2007-08-22 | 2013-02-20 | Allergan, Inc. | Therapeutic quinoline and naphthalene derivatives |
| JO3265B1 (ar) | 2008-12-09 | 2018-09-16 | Novartis Ag | مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض |
| US20110112121A1 (en) * | 2009-07-06 | 2011-05-12 | Joerg Berghausen | Pharmaceutical Compositions and Solid Forms |
| CA2824028A1 (en) * | 2011-01-06 | 2012-07-12 | Beta Pharma Canada Inc. | Novel ureas for the treatment and prevention of cancer |
| US10149834B2 (en) | 2011-12-01 | 2018-12-11 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
| US9849095B2 (en) * | 2011-12-01 | 2017-12-26 | Teikoku Seiyaku Co., Ltd. | Ropinirole-containing adhesive patch |
| ES2899726T3 (es) | 2013-04-09 | 2022-03-14 | Guangzhou Kangrui Biological Pharmaceutical Tech Co Ltd | Compuesto antiangiogénesis, intermediario y uso del mismo |
| US9682931B2 (en) * | 2013-11-01 | 2017-06-20 | Ube Industries, Ltd. | Aryloyl(oxy or amino)pentafluorosulfanylbenzene compound, pharmaceutically acceptable salt thereof, and prodrugs thereof |
| JP6879740B2 (ja) | 2013-12-13 | 2021-06-02 | ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド | リンパ形質細胞性リンパ腫を処置する方法 |
| CN104860885B (zh) * | 2014-02-24 | 2017-11-17 | 中国科学院上海药物研究所 | 萘酰胺类化合物、其制备方法和用途 |
| JO3705B1 (ar) * | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| CN107098884A (zh) * | 2016-02-19 | 2017-08-29 | 中国科学院上海药物研究所 | 一类取代的氨基吡啶类化合物及其制备和用途 |
| RU2743170C2 (ru) | 2016-06-01 | 2021-02-15 | Байер Энимал Хелс Гмбх | Замещенные индазолы, пригодные для лечения и предупреждения аллергических и/или воспалительных заболеваний у животных |
| US20230285389A1 (en) * | 2020-02-28 | 2023-09-14 | Shanghai Runshi Medical Technology Co., Ltd | Use of csf-1r kinase inhibitor |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| US5879690A (en) * | 1995-09-07 | 1999-03-09 | Perricone; Nicholas V. | Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers |
| US6355657B1 (en) * | 1998-12-30 | 2002-03-12 | Atrix Laboratories, Inc. | System for percutaneous delivery of opioid analgesics |
| AU6998000A (en) * | 1999-08-27 | 2001-03-26 | Boehringer Ingelheim Pharma Kg | Substituted indolinones as tyrosine kinase inhibitors |
| ES2210168T3 (es) * | 2000-06-01 | 2004-07-01 | Watson Pharmaceuticals, Inc. | Dispositivo transdermico de lasofoxileno. |
| JP2004523474A (ja) * | 2000-09-20 | 2004-08-05 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | チロシンキナーゼモジュレーターとしてのピラジン誘導体 |
| ATE419239T1 (de) * | 2000-10-20 | 2009-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung von 4-phenoxy chinolin derivaten |
| DK1423102T3 (da) * | 2001-09-04 | 2008-04-14 | Trommsdorff Arzneimittel | Plaster til behandling af neglevæksts dysfunktioner og lidelser |
| EP1478358B1 (en) * | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| US20040043026A1 (en) * | 2002-05-13 | 2004-03-04 | Tai-Lan Tuan | Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| CN100339376C (zh) * | 2002-08-30 | 2007-09-26 | 卫材R&D管理有限公司 | 含氮芳环衍生物 |
| WO2004103159A2 (en) * | 2003-05-14 | 2004-12-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for modulating endometrium |
| CA2536788A1 (en) * | 2003-08-29 | 2005-03-10 | Pfizer Inc. | Naphthalene carboxamides and their derivatives useful as new anti-angiogenic agents |
| WO2005069906A2 (en) * | 2004-01-16 | 2005-08-04 | Yale University | Methods and compositions relating to vascular endothelial growth factor and th2 mediated inflammatory diseases |
| EP1713484A2 (en) * | 2004-01-23 | 2006-10-25 | Amgen Inc. | Compounds and methods of use |
| EP1568368A1 (en) * | 2004-02-26 | 2005-08-31 | Schering Aktiengesellschaft | Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor |
| PE20060664A1 (es) * | 2004-09-15 | 2006-08-04 | Novartis Ag | Amidas biciclicas como inhibidores de cinasa |
-
2006
- 2006-09-08 GT GT200600411A patent/GT200600411A/es unknown
- 2006-09-10 SA SA6270315A patent/SA06270315B1/ar unknown
- 2006-09-11 AR ARP060103941A patent/AR056194A1/es not_active Application Discontinuation
- 2006-09-12 AU AU2006291526A patent/AU2006291526B2/en not_active Ceased
- 2006-09-12 PE PE2006001109A patent/PE20070457A1/es not_active Application Discontinuation
- 2006-09-12 NZ NZ566474A patent/NZ566474A/en not_active IP Right Cessation
- 2006-09-12 BR BRPI0615881-1A patent/BRPI0615881A2/pt not_active IP Right Cessation
- 2006-09-12 TW TW095133706A patent/TWI325321B/zh not_active IP Right Cessation
- 2006-09-12 JP JP2008530401A patent/JP2009507871A/ja active Pending
- 2006-09-12 KR KR1020087008666A patent/KR20080058376A/ko not_active Ceased
- 2006-09-12 WO PCT/EP2006/008857 patent/WO2007031265A2/en not_active Ceased
- 2006-09-12 SG SG201006609-0A patent/SG165371A1/en unknown
- 2006-09-12 MY MYPI20080558A patent/MY145751A/en unknown
- 2006-09-12 US US12/066,726 patent/US20080306058A1/en not_active Abandoned
- 2006-09-12 CA CA002621399A patent/CA2621399A1/en not_active Abandoned
- 2006-09-12 RU RU2008114048/15A patent/RU2424804C2/ru not_active IP Right Cessation
- 2006-09-12 AT AT06791989T patent/ATE555790T1/de active
- 2006-09-12 EP EP06791989A patent/EP1945217B1/en not_active Not-in-force
-
2008
- 2008-03-06 IL IL189984A patent/IL189984A0/en unknown
- 2008-03-11 EC EC2008008259A patent/ECSP088259A/es unknown
- 2008-03-12 TN TNP2008000112A patent/TNSN08112A1/en unknown
- 2008-03-17 MA MA30759A patent/MA29788B1/fr unknown
- 2008-04-14 NO NO20081807A patent/NO20081807L/no not_active Application Discontinuation
-
2012
- 2012-03-15 US US13/420,993 patent/US20120172386A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| TNSN08112A1 (en) | 2009-07-14 |
| US20080306058A1 (en) | 2008-12-11 |
| MA29788B1 (fr) | 2008-09-01 |
| SG165371A1 (en) | 2010-10-28 |
| TWI325321B (en) | 2010-06-01 |
| GT200600411A (es) | 2007-05-21 |
| PE20070457A1 (es) | 2007-06-06 |
| MY145751A (en) | 2012-03-30 |
| WO2007031265A3 (en) | 2007-07-12 |
| KR20080058376A (ko) | 2008-06-25 |
| CA2621399A1 (en) | 2007-03-22 |
| WO2007031265A2 (en) | 2007-03-22 |
| EP1945217B1 (en) | 2012-05-02 |
| RU2424804C2 (ru) | 2011-07-27 |
| JP2009507871A (ja) | 2009-02-26 |
| RU2008114048A (ru) | 2009-10-20 |
| ECSP088259A (es) | 2008-04-28 |
| TW200744600A (en) | 2007-12-16 |
| BRPI0615881A2 (pt) | 2011-05-31 |
| NO20081807L (no) | 2008-05-16 |
| SA06270315B1 (ar) | 2010-12-21 |
| NZ566474A (en) | 2011-05-27 |
| AU2006291526A1 (en) | 2007-03-22 |
| IL189984A0 (en) | 2008-11-03 |
| EP1945217A2 (en) | 2008-07-23 |
| US20120172386A1 (en) | 2012-07-05 |
| AU2006291526B2 (en) | 2010-07-29 |
| ATE555790T1 (de) | 2012-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056194A1 (es) | Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular | |
| AR050932A1 (es) | Amidas biciclicas como inhibidores de cinasa | |
| PE20240879A1 (es) | Inhibidor sos1 y uso del mismo | |
| ES2564179T3 (es) | Derivados de 4-(p-quinonil)-2-hidroxibutanamida para tratamiento de enfermedades mitocondriales | |
| AR055774A1 (es) | Fenilacetamidas apropiadas como inhibidores de proteina quinasa | |
| AR105640A1 (es) | Derivados heterobicíclicos microbicidas | |
| CO6270320A2 (es) | Derivados de piperidina utiles como antagonistas del receptor orexina | |
| AR054809A1 (es) | Compuestos de amino -5-heteroarilo (5 miembros) imidazolona y su uso para la modulacion de la b- secretasa | |
| AR091279A1 (es) | Inhibidores macrociclicos de virus flaviviridae | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| ES2531023T3 (es) | Derivados de isoxazolo-piridina | |
| AR072936A1 (es) | Derivados piridazin y pirimidin condensados con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos como agentes anticancer. | |
| AR053436A1 (es) | Iderivados de 3-(indazol-5-il)-(1,2,4)triazina inhibidores de quinasas | |
| AR088449A1 (es) | Benzilindazoles sustituidos | |
| CO6160266A2 (es) | Derivado de oxopirazina y herbicida | |
| CO6300865A2 (es) | Derivados polisustituidos de 2 aril-6-fenil-imidazo[1,2-a]piridinas su preparacion y su aplicacion en terapeutica | |
| AR082004A1 (es) | Compuestos de fusion de piridina | |
| AR052343A1 (es) | Analogos de tetrahidroquinolina como agonistas muscarinicos | |
| AR083070A1 (es) | Analogos de nucleotidos sustituidos con heterociclos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos para tratar enfermedades virales, en particular infecciones por vhc | |
| AR082696A1 (es) | Derivados heterociclicos nitrogenados de 1,2,4-oxadiazol, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades cardiovasculares e inflamatorias, entre otras | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| PE20081844A1 (es) | DERIVADOS DE INDOL-3-IL-CARBONIL-AZASPIROPIPERIDINA COMO ANTAGONISTAS DEL RECEPTOR V1a | |
| CO6020016A1 (es) | Derivados de 1,2,4,5 tetrahidro-3h-benzapezinas su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |